RxDoctor Payments Data

Shana Eborn, MD

Family Medicine · Salt Lake City, UTNPI 1780615658

Payments from drug & device makers

$6,744in general payments, 2019–2025

Across 409 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boehringer Ingelheim$437
  • Lilly USA, LLC$357
  • Pfizer$353
  • Amgen$326
  • Novo Nordisk$325
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$6,744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,744 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$65,930
Medicare patients
127
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$73,413
FarxigaDapagliflozin Propanediol49$45,963
OzempicSemaglutide12$21,386
EliquisApixaban16$17,684
TrulicityDulaglutide12$11,143
DayvigoLemborexant12$3,962
Atorvastatin Calcium248$3,168
Gabapentin64$2,442
Omeprazole95$2,151
Levothyroxine Sodium195$1,825
SynthroidLevothyroxine Sodium24$1,784
Metformin Hcl127$1,620
PaxlovidNirmatrelvir/Ritonavir14$1,429
Metformin Hcl ErMetformin Hcl98$1,367
Duloxetine Hcl55$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$357$84,55775 claims
AstraZenecaFarxiga$288$45,96349 claims
Novo NordiskOzempic$325$21,38612 claims
PfizerEliquis, Paxlovid$353$19,11330 claims
AbbVieSynthroid$1,401$1,78424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →